U.S., July 10 -- ClinicalTrials.gov registry received information related to the study (NCT07055594) titled 'A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors' on June 18.
Brief Summary: The investigational drug, SOA101, is a nanobody-based trispecific antibody T cell engager targeting PD-L1/HLA-G/CD3. This is a Phase I/IIa study including dose-escalation, dose optimization and dose expansion parts to exam safety, tolerability, pharmacokinetics, immunogenecity and efficacy of SOA101 on advanced or metastatic solid tumor treatment.
Study Start Date: July, 2025
Study Type: INTERVENTIONAL
Condition:
Solid Tumors
Intervention:
DRUG: SOA101
Participants will receive SOA101. The ...